Carcinoid tumor market seen growing to $2.88 billion by 2030

The Business Research Company projects the carcinoid tumor market will rise from $1.96 billion in 2026 to $2.88 billion by 2030, driven by obesity, new therapies and broader precision oncology use. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - The carcinoid tumor market is tied to treatment for a rare cancer type that can be difficult to diagnose and manage. - Faster market growth points to rising demand for specialized oncology care, targeted drugs and long-term disease management. - The report also links market expansion to broader trends in rare-cancer research and precision medicine.

What happened: - The Business Research Company released a carcinoid tumor market report covering market size, trends and global forecasts for 2026 to 2035. - The market value is projected to grow from $1.77 billion in 2025 to $1.96 billion in 2026. - The report forecasts the market will reach $2.88 billion by 2030. - The report includes a free sample available here. - The full report is posted here.

The details: - The report says the 2025 to 2026 increase reflects a 10.5% CAGR. - The 2030 forecast implies a 10.1% CAGR from 2026 onward. - Historic growth has been driven by greater awareness of rare cancers, more oncology care centers, wider use of somatostatin analog treatments, more specialized cancer clinics and progress in neuroendocrine tumor research. - The carcinoid tumor market covers rare, slow-growing neuroendocrine tumors often found in the gastrointestinal tract or lungs. - These tumors originate from enterochromaffin cells that produce hormones such as serotonin. - Symptoms vary by tumor location and hormone secretion, and some cases can lead to carcinoid syndrome. - The report identifies obesity as a major growth driver. - Obesity is defined as a body mass index of 30 or above. - The report links obesity to chronic inflammation, insulin resistance and increased growth-factor signaling that can support tumor growth. - The report cites UK Office for Health Improvement and Disparities data showing 64.5% of adults in England were overweight or obese in 2023-2024, up from 64.0% the year before. - Other growth factors include improved diagnostic techniques, expanded oncology infrastructure and increased awareness of neuroendocrine tumors. - North America held the largest market share in 2025. - Asia-Pacific is forecast to grow the fastest in the coming years. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests the market is moving from a niche oncology segment toward broader commercial interest in targeted and personalized care. - The emphasis on early diagnosis and long-term management suggests future competition may center on detection, combination therapies and patient quality-of-life outcomes. - North America's lead reflects stronger research capacity and faster adoption of new therapies, while Asia-Pacific's outlook points to expanding demand and infrastructure.

What's next: - The report expects more targeted neuroendocrine tumor treatments, more combination drug regimens and wider use of personalized treatment plans. - The Business Research Company also expects continued expansion of specialized oncology centers and stronger long-term disease management strategies. - Future market growth will likely depend on how quickly precision oncology and rare-cancer research translate into clinical adoption.